Birabresib

DRUG3 trials

Sponsors

Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Merck Sharp & Dohme LLC

Conditions

CRPCCastrate-resistant Prostate CancerCastration-resistant Prostate Cancer (CRPC)Glioblastoma MultiformeNUT Midline CarcinomaNUT Midline Carcinoma (NMC)Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation

Phase 1

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

CompletedNCT02259114

Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Castrate-resistant Prostate Cancer, CRPC, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation +3

Start: 2014-10-23End: 2017-03-03Updated: 2021-01-26

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

TerminatedNCT02698176

Merck Sharp & Dohme LLCCastration-resistant Prostate Cancer (CRPC), Non-small Cell Lung Cancer (NSCLC), NUT Midline Carcinoma (NMC) +1

Start: 2016-05-04End: 2017-04-26Updated: 2021-01-27

Phase 2

A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)

TerminatedNCT02296476

Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Glioblastoma Multiforme

Start: 2014-10-29End: 2015-10-20Updated: 2021-01-26

Related Papers

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

Oncotarget2016-12-0792 citations

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations

Oncotarget2016-11-0758 citations

Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients (pts) with recurrent glioblastoma (GB).

Journal of Clinical Oncology2016-05-2020 citations